Literature DB >> 11832681

The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model.

Elizabeth Bogard1, Karen M Kuntz.   

Abstract

Because of the variability of HIV, the first AIDS vaccine is likely to be only partially effective. There is some concern among scientists that a low-efficacy vaccine could worsen the HIV epidemic if vaccinated individuals increase their risk behavior under the false assumption of immunity. To address this concern, we constructed a dynamic compartmental model that simulated the course of the HIV/AIDS epidemic in a population of injection drug users in Bangkok, Thailand. The model calculated long-term HIV prevalence, number of AIDS cases, and total population size for two scenarios: vaccination program versus no vaccination program. We used sensitivity analyses to evaluate the impact of postvaccination risk behavior change on HIV prevalence. A 75% effective vaccine led to a 40-year HIV prevalence of 37% with vaccination and 50% without vaccination. Postvaccination behavior change had only a limited effect on the results with a 75% effective vaccine but a significant effect with a 30% effective vaccine. If 90% of low-risk individuals responded to a 30% effective vaccine with increased high-risk behavior, the benefit of vaccination disappeared. These results agree with analyses of the epidemic among gay men. If injection drug behavior is indeed modifiable, our findings have significant policy and planning implications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832681     DOI: 10.1097/00042560-200202010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

1.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

2.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

3.  Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.

Authors:  Miles P Davenport; Ruy M Ribeiro; Dennis L Chao; Alan S Perelson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.

Authors:  Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

Review 5.  Apples and oranges? Interpreting success in HIV prevention trials.

Authors:  Lori L Heise; Charlotte Watts; Anna Foss; James Trussell; Peter Vickerman; Richard Hayes; Sheena McCormack
Journal:  Contraception       Date:  2010-08-07       Impact factor: 3.375

6.  Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand.

Authors:  Pattara Leelahavarong; Yot Teerawattananon; Pitsaphun Werayingyong; Chutima Akaleephan; Nakorn Premsri; Chawetsan Namwat; Wiwat Peerapatanapokin; Viroj Tangcharoensathien
Journal:  BMC Public Health       Date:  2011-07-05       Impact factor: 3.295

7.  Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa.

Authors:  Carlo Zambonelli; Antu K Dey; Susan Hilt; Samuel Stephenson; Eden P Go; Daniel F Clark; Mark Wininger; Celia Labranche; David Montefiori; Hua-Xin Liao; Ronald I Swanstrom; Heather Desaire; Barton F Haynes; Andrea Carfi; Susan W Barnett
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

Review 8.  Operations research in global health: a scoping review with a focus on the themes of health equity and impact.

Authors:  Beverly D Bradley; Tiffany Jung; Ananya Tandon-Verma; Bassem Khoury; Timothy C Y Chan; Yu-Ling Cheng
Journal:  Health Res Policy Syst       Date:  2017-04-18

9.  Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Authors:  April M Young; Daniel S Halgin; Ralph J DiClemente; Claire E Sterk; Jennifer R Havens
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

10.  A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice.

Authors:  Svetlana Rabinovich; Rebecca L R Powell; Ross W B Lindsay; Maoli Yuan; Alexei Carpov; Aaron Wilson; Mary Lopez; John W Coleman; Denise Wagner; Palka Sharma; Marina Kemelman; Kevin J Wright; John P Seabrook; Heather Arendt; Jennifer Martinez; Joanne DeStefano; Maria J Chiuchiolo; Christopher L Parks
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.